Background The Dermatology Life Quality Index (DLQI) is the most frequently used health-related quality of life
Introduction
In past decades, health-related quality of life (HRQoL) has become a major outcomes parameter in dermatology. As recommended by regulatory authorities, measurement of HRQoL is included in almost all clinical trials. 1, 2 In clinical care, the use of patient-relevant outcomes has likewise been recommended by guidelines and consensus documents. 3, 4 Recommendations for the use of HRQoL instruments have been issued. 5 The Dermatology Life Quality Index (DLQI) has become the most frequently used disease-specific quality of life instrument for skin diseases. [6] [7] [8] [9] [10] It has gained high acceptance due to good feasibility and ease of use. Moreover, an anchor-based system of severity classification has been developed, and attempts to establish minimum clinically important differences have been made. 11 However, some drawbacks of the DLQI have been discussed and need to be taken into account. [12] [13] [14] Moreover, there are obviously limitations with respect to content validity when indications other than chronic inflammatory skin diseases are investigated. Another potential limitation is its construction as a sum scored HRQoL instrument combined with the fact that missing values and items marked as 'not relevant' are scored as 0 = 'no impairment'. Hence, patients who mark an item as 'not relevant', which is an option in 8 out of 10 items, are considered to be unaffected in that aspect of life. This raises the question whether there are disease-related reasons for considering an item to be 'not relevant'. This could be related to being too impaired by the skin disease to take part in certain areas of life. If so, patients would be ascribed a lower overall DLQI score (=higher HRQoL) in the absence of the corresponding HRQoL.
A potential bias in the DLQI score arising from this aspect has not yet been systematically analysed in the literature.
Hence, the current study was conducted in a large cohort of psoriasis patients in order to assess the extent of bias that may result from the technical construction of the DLQI, specifically in terms of the treatment of 'not relevant' declarations.
The research questions were as follows: 1 What is the proportion of psoriasis patients with missing answers and items declared to be not relevant? 2 Are there any differences with respect to severity indicators between psoriasis patients who state 'not relevant' and those who state 'my skin problem has not at all affected this aspect of life over the last week' ('not at all') for particular DLQI items?
Methods

Study design
Data were obtained from a large cross-sectional nationwide study conducted with adult patients with psoriasis vulgaris in dermatological care in Germany. 15 Data collection took place between January 2013 and March 2014. Patient-related outcomes were gathered by means of questionnaires with both practitioner and patient components.
Outcomes
Like the other instruments, the DLQI was used in a validated German translation. 16 Based on ten questions about the impact of the skin disease and its treatment on different aspects of the patient 0 s HRQoL over the last week, the DLQI sum score is calculated by summing up the score of each item. Questions are scored on a four-point Likert scale: 0, not at all/not relevant; 1, a little; 2, a lot; and 3, very much. The total DLQI sum score can range from 0 to 30, with lower scores indicating better HRQoL. The patient 0 s subjective health state was measured by means of the German version of the visual analogue scale (EQ VAS) of the EQ-5D 17 in which the patient assesses his/her own current health state on a scale from 0 ('worst imaginable health state') to 100 ('best imaginable health state'). Severity of psoriasis was measured by means of the German version of Psoriasis Area and Severity Index (PASI). 18 This score combines the severity ratings of three target symptoms (erythema, infiltration and desquamation) and the involvement of the four main body areas (head, trunk, upper and lower extremities). The PASI score ranges from 0 to 72. Higher scores indicate higher severity of the psoriasis.
Statistical analysis
All data were described with standard statistical parameters (frequencies for categorical data; mean value and standard deviation for continuous data). Means of two groups were compared by unpaired t-tests. Differences with a probability of a type I (a) error of ≤0.05 were considered as statistically significant in all analyses. Each unpaired t-test was supplemented by effect-size determination (Cohen's d). It is determined by calculating the mean difference between two groups and divided by the pooled standard deviation. According to Cohen, sizes of 0.2, 0.5 and 0.8, respectively, represent weak, medium and strong effects in unpaired t-tests. 19 The analysis was performed using SPSS Statistics 23 for Microsoft Windows (IBM Corp, Armonk, NY, USA).
Results
Overall, n = 1243 patients with psoriasis from 82 dermatological centres were included. Mean age was 52 years; proportion of female patients was 43.4% (Table 1) . 6.0% of the patients had at least one missing value in the DLQI. By contrast, the proportion of items declared 'not relevant' was considerable (Fig. 1) . The items most frequently marked as 'not relevant' were item 7 ('work and study', 28.1%), item 6 ('sport, exercise', 26.0%), item 9 ('sexual relationships', 22.1%) and item 8 ('personal relationships', 15.8%).
Overall, 48.7% of patients answered all 10 items without 'not relevant' statements or missing answers. By contrast, the proportion of patients with at least one item declared to be not relevant was 48.0% (1-3 items considered 'not relevant': 36.1%; >3: 11.9%) (Fig. 2) .
Subjective health (EuroQoL Visual Analogue Scale, EQ VAS) and disease severity (Psoriasis Area and Severity Index, PASI) differed between patients who stated 'not relevant' and those who stated 'not at all' regarding the same DLQI item. Except for the PASI difference between patients answering item 4 ('clothing'), patients who declared a DLQI item to be not relevant displayed a higher disease severity and a lower subjective health ( Table 2 ).
Discussion
The objective of the present study was to identify a potential bias of the Dermatology Life Quality Index in the outcomes measurement of disease-specific HRQoL in psoriasis as a consequence of items declared to be not relevant. This questionnaire is the most frequently used instrument for the assessment of quality of life in skin diseases worldwide. Accordingly, any potential bias associated with its use is of great interest. Unlike formal validity, which has been described in a number of previous studies, 6 no systematic investigations have been conducted analysing the robustness of the instrument with respect to relevant scaling properties, such as the treatment of items declared to be not relevant. Many regulatory bodies and reimbursement agencies require the DLQI as a measure of patient burden. In many countries, a DLQI >10 is the qualifying threshold for the indication of systemic treatment. Moreover, the benefit assessment for systemic drugs largely depends on effectiveness in patients with moderate to severe disease, defined -in the field of psoriasis -as DLQI and body surface area (BSA) or PASI >10. 3 Hence, any uncertainty in achieving PASI >10 directly impacts reimbursement, treatment indication and access to drugs for patients under real-world conditions. Owing to the use of a sum score built of 10 items that includes 8 items with a 'not relevant' option that is scored as 0 = 'no impairment', any item missing or declared to be not relevant for reasons other than a lack of disease burden may prejudice fair HRQoL assessments. The present data for psoriasis support the previous findings of good feasibility and acceptability of the DLQI questionnaire. 8, 20 By contrast, the high proportion of patients declaring 'not relevant' at least once in the DLQI indicates that this is not a negligible phenomenon. The largest number of 'not relevant' responses was found for the questions on impairment in work and school, sport, sexual relationships, as well as in social activities. Hence, persons with a lack of social contacts, sexual activity and employment, who rate those items as not relevant because they do not experience those areas of life show a lower quality of life burden according to the DLQI. However, this is precisely the 9. Over the last week, how much has your skin caused any sexual difficulties?
10. Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time? population known to be at high risk of psoriasis and related negative impacts on their life. Hence, the presumed underestimation would most likely affect a group that is actually affected by a high disease burden. This interpretation is supported by the finding that the disease-related burden in patients with psoriasis stating 'not relevant' is higher than that of patients stating 'my skin problem has not at all affected this aspect of life' in most of the DLQI items with a 'not relevant' option. This comparison is of particular interest because both statements are treated the same manner, by scoring them 0 (='no impairment') for each item, according to the DLQI instructions. A possible limitation of this study is that the specific phrasing of the response options in a specific language may influence how patients respond, which in turn may have a (probably small) bearing whether these results from a German study can be generalized to other language versions of the DLQI instrument. This question should be addressed in future studies.
Taken together, the data suggest that considering an item to be not relevant because of disease-related disabilities to participate in sports, social events and other activities of everyday life should be treated differently in HRQoL assessment undertaken by means of DLQI. We also recommend the development of further methodology for HRQoL assessment that can be unambiguously applied to all patients with a given skin disease.
